Apelin in Willis Ekbom Disease

Oxidative Stress and Apelin Level in Willis Ekbom Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02264600

Enrollment

Registered

2014-10-15

Start date

2014-11-30

Completion date

2015-04-30

Last updated

2014-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Restless Legs Syndrome

Keywords

Restless Legs Syndrome, Apelin, Oxidative Stress

Brief summary

The purpose of this study is to assess apelin level in patients with Willis-Ekbom Disease (WED) as known Restless Legs Syndrome (RLS). Cardiovascular complications of WED have been reported in recent studies. Increased oxidative stress is thought to play an important role in cardiovascular complications of WED patients. Apelin is a novel described antioxidant bioactive peptide. The investigators hypothesize that patients with WED have lower plasma apelin level than healthy subjects based on presence of oxidative stress of WED.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients diagnosed as RLS/WED according to International Classification of Sleep Disorders (ICSD-3) criteria * Patients with idiopathic RLS/WED * Moderate and severe RLS/WED according to International Restless Legs Syndrome Rating Scale * Periodic Leg Movements Index above 5 in polysomnography record * BMI below 25

Exclusion criteria

* Disorders which cause symptomatic RLS(Iron deficiency anemia, kidney failure, diabetes mellitus, pregnancy, Parkinson's disease, multiple sclerosis, neuropathy) * Systemic diseases which cause possible oxidative stress status (cardiovascular diseases, obesity, diabetes mellitus, use of any medical drugs especially ACE inhibitors e.g.) * Another sleep disorder

Design outcomes

Primary

Measure	Time frame
Serum apelin level in WED patients and healthy controls	Two months

Contacts

Primary ContactSelda Korkmaz, Assist. Prof. Dr.

korkmazs78@gmail.com00905325807889

Backup ContactTugce Bilecenoglu, M.D.

nedimetugche@yahoo.com00905386275515

Outcome results